Recently, well-respected industry media “Healthcare Executive Magazine” published the list of the 2023 "Top 100 Chinese Innovative Pharmaceutical Companies", in which Hansoh Pharma made it into the top tier of the "Top 100 Chinese Innovative Pharmaceutical Companies" for the fifth year in a row, with a noticeable rise in its ranking this year.
The list of "Top 100 Chinese Innovative Pharmaceutical Companies" is compiled by “Healthcare Executive Magazine” based on Derwent innovation patent data, Cortellis™ competitive intelligence and clinical trial data, and is measured according to four key indicators: the number of patents granted, the total number of patent citations, the number of clinical trials, and the number of innovative drugs approved and released on the market. The list evaluates the foundation process, and achievements of companies surrounding the innovation from multiple perspectives and dimensions, and aims to select industry benchmark enterprises that act as role models and leaders, advancing the potential for innovation in the industry.
Hansoh Pharma is a leading pharmaceutical company driving innovation in China. Hansoh has gained a foothold in global scientific and technological frontiers, and is actively involved in international partnerships, accumulating considerable innovative strength and fruitful innovative achievements. Up until now, Hansoh Pharma has successfully released seven innovative drugs onto the market, and is conducting more than 40 clinical trials for over 30 innovative drugs, covering areas such as monoclonal antibodies, bispecific antibodies, ADC drugs, siRNA, and fusion proteins. A stream of successfully marketed innovative drugs has become the leading force driving the company's development, and these innovative drugs have generated over 60% of the company's revenue, enabling it to enter a new cycle of growth.
In 2023, Hansoh Pharma’s B7-H3 ADC (HS-20093), c-MET TKI (HS-10241), RET inhibitor (HS-10365), and many other in-progress studies achieved significant clinical progress and received internationally-acclaimed recognition. Our marketed product—the invention patent for China's first original third-generation innovative drug EGFR-TKI Aumolertinib, "EGFR inhibitor and its preparation and application" (Patent No. ZL 201580045311.0)— won the 24th "China Patent Gold Award", further proving Hansoh Pharma's superb innovative prowess and the value of the independently-developed product. During the first half of 2023, Hansoh Pharma obtained a total of 28 authorized patents in China (including 8 in Hong Kong, Macau, and Taiwan), and 13 authorized patents overseas. Behind such accelerated innovation outcomes is continuous input into innovation, and R&D expenditure by Hansoh Pharma rose 25.8% in the first half of 2023, maintaining its leading position in the industry.
Empowered by technology, driven by innovation. Hansoh Pharma will always focus on deep-rooted clinical needs, adhere to the mission of "continuous innovation to improve the quality of human life", continuously refine its R&D strategies, improve the efficiency of R&D, enrich the global pipeline of more effective and differentiated high-potential products, and accelerate the implementation of innovation research results to benefit a wide range of patients.
